This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.
ANIPNegative Net Change KODPositive Net Change INDVPositive Net Change
biotechs
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
by Zacks Equity Research
Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026 decision.
NVSNegative Net Change BIIBPositive Net Change RHHBYPositive Net Change SRRKNegative Net Change
biotechs medical pharmaceuticals
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
by Zacks Equity Research
Agios Pharmaceuticals jumps 14% as it moves toward accelerated FDA approval for mitapivat in sickle cell disease after key regulatory feedback.
AGIOPositive Net Change ANIPNegative Net Change INDVPositive Net Change
biotechs
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
by Zacks Equity Research
AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.
AZNPositive Net Change PRTAPositive Net Change ANIPNegative Net Change LQDANegative Net Change
biotechs
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?
by Ekta Bagri
ADMA rides on surging Asceniv demand, expanding payer coverage, and stronger plasma supply deals to drive rapid revenue growth through 2027.
GRFSPositive Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
by Zacks Equity Research
Novo Nordisk stock jumps after launching a Wegovy subscription plan to cut costs, expand telehealth access and improve treatment adherence for sustained obesity care.
NVOPositive Net Change LLYPositive Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
by Zacks Equity Research
BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenues and strengthening its push into high-growth rare disease markets.
BIIBPositive Net Change ADMANegative Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
by Zacks Equity Research
Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.
BIIBPositive Net Change LLYPositive Net Change GILDNegative Net Change
biotechs medical pharmaceuticals
Bayer Wins EC Approval to Expand Kerendia in Heart Failure Treatment
by Zacks Equity Research
Bayer wins EU nod to expand Kerendia's use in heart failure, backed by strong phase III data, boosting a key drug driving growth and portfolio momentum.
REGNPositive Net Change JNJPositive Net Change BAYRYNo Net Change
biotechnology biotechs medical pharmaceuticals
Is ANIP Undervalued? How to Read Its 9.3x Forward P/E
by Sundeep Ganoria
ANI Pharmaceuticals trades at just 9.3x forward earnings, far below peers - raising a key question: is this a bargain or a signal of execution risks ahead?
REGNPositive Net Change ABBVPositive Net Change ANIPNegative Net Change
biotechs medical pharmaceuticals